Related references
Note: Only part of the references are listed.State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018
Nicole C. Foster et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Glycemic Targets: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
William M. Steinberg et al.
DIABETES CARE (2017)
Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program
William M. Steinberg et al.
DIABETES CARE (2017)
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Bo Ahren et al.
DIABETES CARE (2016)
Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks
Nitesh D. Kuhadiya et al.
DIABETES CARE (2016)
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
Chantal Mathieu et al.
DIABETES CARE (2016)
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Thomas Fremming Dejgaard et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
Christian S. Frandsen et al.
DIABETES CARE (2015)
Current State of Type 1 Diabetes Treatment in the US: Updated Data From the T1D Exchange Clinic Registry
Kellee M. Miller et al.
DIABETES CARE (2015)
Gastric emptying and glycaemia in health and diabetes mellitus
Liza K. Phillips et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Type 1 diabetes, metabolic syndrome and cardiovascular risk
Juan J. Chillaron et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
LIRAGLUTIDE AS ADDITIONAL TREATMENT TO INSULIN IN OBESE PATIENTS WITH TYPE 1 DIABETES MELLITUS
Nitesh D. Kuhadiya et al.
ENDOCRINE PRACTICE (2013)
Insulin-Pump Therapy for Type 1 Diabetes Mellitus
John C. Pickup
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
Urd Kielgast et al.
DIABETES CARE (2011)
Temporal patterns in overweight and obesity in Type 1 diabetes
B. Conway et al.
DIABETIC MEDICINE (2010)
Weight Loss Reduces Liver Fat and Improves Hepatic and Skeletal Muscle Insulin Sensitivity in Obese Adolescents
Bernadette E. Vitola et al.
OBESITY (2009)
Obesity and health-related quality of life: a cross-sectional analysis of the US population
MK Hassan et al.
INTERNATIONAL JOURNAL OF OBESITY (2003)
Impaired β-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose
CJ Greenbaum et al.
DIABETES (2002)
Share Paper
